hereditary angioedema
Rare disease · 2011–2024
5decisions
3medicines
4carried consumer input
90individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| garadacimab Routine prevention of hereditary angioedema (HAE) attacks in adult and adolescent patients aged 12 years and older with HAE Types I and II. | Nov 2024 | Recommended with restriction | 20 individuals HAE Australia |
| lanadelumab Routine prophylaxis of recurrent attacks of hereditary angioedema (HAE) in patients who experienced at least 12 treated acute HAE attacks within a 6-month… | Jul 2021 | Recommended | 26 individuals HAE Australia |
| lanadelumab Routine (long-term) prophylaxis of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. | Jul 2020 | Deferred | 24 individuals |
| lanadelumab Routine prophylaxis of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older, particularly those for whom danazol is not… | Jul 2019 | Recommended with restriction | 20 individuals |
| icatibant Anticipated emergency treatment of an acute attack of hereditary angioedema in a patient with confirmed diagnosis of C1-esterase inhibitor deficiency, with… | Jul 2011 | Not recommended | no section in document |
Who spoke
HAE Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.